Advanced non-squamous non-small cell lung cancer
Conditions
Interventions
Cisplatin+S-1+Bev
Cisplatin+PEM+Bev
Sponsors
Gunma Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Eligible patients were required to have: histologically and/or cytologically proven unresectable stage IIIB or IV non-squamous NSCLC; no previous chemotherapy or radiotherapy; a performance status (PS) of 0-1 on the Eastern Cooperative Oncology Group; an age between 20 years and 74 years; a life expectancy of 12 weeks or more; adequate bone marrow reserve (leukocyte count > 4000 mm-3, neutrophil count > 2000 mm-3, platelet count > 100000 mm-3, and hemoglobin > 10 g dL-1); normal liver function (total serum bilirubin < 1.5 mg dL-1, and aspartate transaminase (AST), alanine transaminase (ALT) less than twice the upper limit of the normal range), normal renal function (normal serum creatinine and blood urea nitrogen levels) and pulmonary function (PaO2 > 70 torr). Signed informed consent
Exclusion criteria
Exclusion criteria: Patients were excluded if they had malignant pleural or pericardial effusion, active double cancer, a concomitant serious illness, such as uncontrolled angina pectoris, myocardial infarction in the previous 3 months, heart failure, uncontrolled diabetes mellitus, uncontrolled hypertension, interstitial pneumonia or lung disease, infection or other diseases contraindicating chemotherapy or radiotherapy, pregnancy, or breast-feeding. Judging of inappropriate condition for this study by physian
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression-free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival, overal response rate, time to treatment failure, safety | — |
Countries
Japan
Contacts
Public ContactKyoichi Kaira
Gunma University Hospital Department of Respiratory Medicine
Outcome results
None listed